[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360021-105":59,"doc-detail-360021-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pharmacokinetic-drugdrug-interaction-potential-of-oral-anticancer-drugs","Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs","","The study compiles clinically relevant pharmacokinetic (PK) drug–drug interaction (DDI) mechanisms for FDA-approved oral anticancer drugs (OADs) and quantifies the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers. OADs approved through January 2023 were mapped to DDI mechanisms using drug labels and primary literature requiring ≥2-fold exposure change or significant adverse outcomes. Records from 3,697 patients were retrospectively reviewed to identify overlapping prescriptions; FDA labels for 99 OADs and 239 studies produced 748 drug–drug pairs for analysis. Findings show 85.9% of OADs with at least one DDI mechanism and ~17.4% of patients with ≥1 PDDI, commonly involving CYP3A or CYP2D6 perpetrator roles, while 14 drugs had clinically relevant mechanisms without actionable label recommendations.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pharmacokinetic-drugdrug-interaction-potential-of-oral-anticancer-drugs/360021/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pharmacokinetic-drugdrug-interaction-potential-of-oral-anticancer-drugs/360021.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the primary objective of this study?","Question",{"text":113,"@type":114},"To compile clinically relevant pharmacokinetic (PK) DDI mechanisms for oral anticancer drugs (OADs) and to assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were DDI mechanisms assigned to oral anticancer drugs?",{"text":118,"@type":114},"OADs approved through January 2023 were assigned DDI mechanisms based on drug labels and primary literature demonstrating ≥2-fold exposure changes or significant adverse health outcomes during co-administration.",{"name":120,"@type":111,"acceptedAnswer":121},"What proportion of patients had a potential PK DDI and which enzyme pathways were most common?",{"text":122,"@type":114},"Among patients prescribed at least one OAD, 17.4% had at least one PDDI. Most commonly, OADs acted as CYP3A or CYP2D6 perpetrators.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360021,1790650534,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs  \nFatimahAlhurayri 1,2, Islam R. Younis3  , Shadia I. Jalal4, Theodore F. Logan4, Rohan Maniar4, Steven M. Bray5, Sara K. Quinney1,6  , Zeruesenay Desta 1,6  , Todd C. Skaar 1,6  , James E. Tisdale 1,6  and Tyler Shugg1,6,*   \nDrug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs) . Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers. OADs approved through January 2023 were assigned DDI mechanisms based on studies obtained from drug labels and primary literature showing ≥ 2-fold exposure change or significant adverse health outcomes during co-administration with interacting drugs. Electronic health records of 3,697 solid cancer patients were reviewed retrospectively to detect PDDIs, defined as overlapping prescriptions of OADs with relevant interacting drugs. FDA labels were reviewed for 99 OADs, and 239 studies were extracted from the primary literature, yielding a total of 748 drug–drug pairs for analysis. Eighty-five OADs (85.9%) had ≥ 1 DDI mechanism. The most common DDI mechanisms were victims with metabolic inducers (71.7%), CYP3A substrates (55.6%), CYP3A perpetrators (29.3%), and victims with acid reducers (17.2%) . Our primary literature search detected clinically relevant DDI mechanisms without actionable recommendations in the drug labels for 14 drugs. Among patients prescribed ≥ 1 OADs (46.9%), 17.4% had ≥ 1 PDDI, most commonly involving OADs acting as CYP3A (58.9%) or CYP2D6 (32.5%) perpetrators. Most OADs (~86%) had ≥ 1 DDI mechanism, and ~17% of solid tumor board patients had a clinically relevant PDDI.  \nStudy Highlights  \nWHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  \n; Oral anticancer drugs have improved the efficacy and convenience of hematology/oncology patient care; however, drug–drug interactions (DDIs) are known to impact the efficacy and safety of many oral anticancer drugs. Due to the dynamic cancer therapeutic market and the multitude of concomitant medications taken by cancer patients, it is a struggle for even the most clinical pharmacology-savvy clinicians to stay abreast of clinically significant DDIs impacting cancer care. WHAT QUESTION DID THIS STUDY ADDRESS?  \n; This investigation (i) comprehensively assessed the pharmacokinetic DDI mechanisms for FDA-approved oral anticancer drugs through January 2023 using drug labels and the primary literature and (ii) characterized the prevalence  \nof potential DDIs in a cohort of patients with advanced solid cancer.  \nWHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?  \n; This study demonstrates that ~86% of oral anticancer drugs have at least one clinically relevant DDI mechanism. Additionally, ~17% of advanced solid cancer patients had potential DDIs likely to impact at least one drug therapy. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?  \n; By comprehensively characterizing DDI mechanisms and providing therapeutic substitution recommendations to avoid DDIs, this manuscript may serve as a reference to oncology clinicians to reduce the frequency and clinical burden of DDIsin their patients.  \nDrug–drug interactions (DDIs) are of particular clinical importance in cancer patients, given the narrow therapeutic indices and the cellular toxicities of many anticancer medications.1,2 Concurrent use  \nof multiple medications (i.e., polypharmacy) is frequent in cancer patients, including medications to treat cancer and to manage cancer therapy-related adverse events, cancer-related symptoms, and  \n1Department of Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, Indiana, USA; 2College of Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 3 Department of Quantitative Pharmacology & Pharmacometrics, Merck & Co. , Rahway, New Jerse","cbCaiextfX8KgQNj","https://ap.wps.com/l/cbCaiextfX8KgQNj","pdf",524259,14,"English","# Study objectives and methods\n## Data sources and DDI mechanism criteria\n## Patient cohort and PDDI definition\n# Results and key findings\n## Prevalence of DDI mechanisms in OADs\n## Prevalence of PDDIs in advanced solid cancer patients\n# Study highlights and clinical implications\n## Current knowledge and research question\n## Added knowledge and potential impact","[{\"question\":\"What was the primary objective of this study?\",\"answer\":\"To compile clinically relevant pharmacokinetic (PK) DDI mechanisms for oral anticancer drugs (OADs) and to assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.\"},{\"question\":\"How were DDI mechanisms assigned to oral anticancer drugs?\",\"answer\":\"OADs approved through January 2023 were assigned DDI mechanisms based on drug labels and primary literature demonstrating ≥2-fold exposure changes or significant adverse health outcomes during co-administration.\"},{\"question\":\"What proportion of patients had a potential PK DDI and which enzyme pathways were most common?\",\"answer\":\"Among patients prescribed at least one OAD, 17.4% had at least one PDDI. Most commonly, OADs acted as CYP3A or CYP2D6 perpetrators.\"}]","Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs | PDF",1790138521,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/715832cb111ec9031011306e7762a94d.webp",983,1296,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e3f7bd2ba6d2380fffb5d124dcadd0f.webp",982,1294,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39e74b08e9b17e6c96616bcbb1d8f176.webp",981,1293,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14e8223a39b80390afa7e51d9690b224.webp",980,1292]